SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Doris E. Payer, Mark Guttman, Stephen J. Kish, Junchao Tong, Antonio Strafella, Martin Zack, John R. Adams, Pablo Rusjan, Sylvain Houle, Yoshiaki Furukawa, Alan A. Wilson, Isabelle Boileau, [11C]-(+)-PHNO PET imaging of dopamine D2/3 receptors in Parkinson's disease with impulse control disorders, Movement Disorders, 2015, 30, 2
  2. 2
    Guadalupe Muñoz-Arenas, Francisco Paz-Bermúdez, Ana Báez-Cordero, René Caballero-Florán, Brenda González-Hernández, Benjamín Florán, I. Daniel Limón, Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry, Synapse, 2015, 69, 3
  3. 3
    Pantelis Stathis, Spiridon Konitsiotis, Angelo Antonini, Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias, Expert Review of Neurotherapeutics, 2015, 15, 2, 207

    CrossRef

  4. 4
    Wataru Sako, Aziz M. Uluğ, David Eidelberg, Movement Disorders, 2015,

    CrossRef

  5. 5
    Catriona J. Wimberley, Kristina Fischer, Anthonin Reilhac, Bernd J. Pichler, Marie Claude Gregoire, A data driven method for estimation of Bavail and appKD using a single injection protocol with [11C]raclopride in the mouse, NeuroImage, 2014, 99, 365

    CrossRef

  6. 6
    Silke Appel-Cresswell, Ali H Rajput, Vesna Sossi, Christina Thompson, Vanessa Silva, Jessamyn McKenzie, Katherine Dinelle, Siobhan E. McCormick, Carles Vilariño-Güell, A. Jon Stoessl, Dennis W Dickson, Chris A. Robinson, Matthew J. Farrer, Alex Rajput, Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism, Movement Disorders, 2014, 29, 13
  7. 7
    Flavia Niccolini, Paul Su, Marios Politis, Dopamine receptor mapping with PET imaging in Parkinson’s disease, Journal of Neurology, 2014, 261, 12, 2251

    CrossRef

  8. 8
    Jia Liu, Jinlong Gao, Shaoang Tu, Shasha Xu, Ying Liu, Weihu Shang, Chenxin Gu, Yiyun Huang, Mei Han, Neuroprotective Effects of Jitai Tablet, a Traditional Chinese Medicine, on the MPTP-Induced Acute Model of Parkinson’s Disease: Involvement of the Dopamine System, Evidence-Based Complementary and Alternative Medicine, 2014, 2014, 1

    CrossRef

  9. 9
    Limin Liu, Wenzhong Zhang, Xiaoli Gong, Xibin Liang, Xiaomin Wang, Relation between microPET imaging and rotational behavior in a parkinsonian rat model induced by medial forebrain bundle axotomy, Behavioural Brain Research, 2014, 265, 148

    CrossRef

  10. 10
    Andre C. Felicio, A. Jon Stoessl, Imaging of the Human Brain in Health and Disease, 2014,

    CrossRef

  11. 11
    Pankaj A. Agarwal, A. Jon Stoessl, Biomarkers for trials of neuroprotection in Parkinson's disease, Movement Disorders, 2013, 28, 1
  12. 12
    S. Al Sweidi, M. Morissette, C. Rouillard, T. Di Paolo, Estrogen receptors and lesion-induced response of striatal dopamine receptors, Neuroscience, 2013, 236, 99

    CrossRef

  13. 13
    J. Sun, N.J. Cairns, J.S. Perlmutter, R.H. Mach, J. Xu, Regulation of dopamine D3 receptor in the striatal regions and substantia nigra in diffuse Lewy body disease, Neuroscience, 2013, 248, 112

    CrossRef

  14. 14
    Y. Kwak, N.I. Bohnen, M.L.T.M. Müller, P. Dayalu, D.T. Burke, R.D. Seidler, Task-dependent interactions between Dopamine D2 receptor polymorphisms and L-DOPA in patients with Parkinson's disease, Behavioural Brain Research, 2013, 245, 128

    CrossRef

  15. 15
    Sylvia Navailles, Philippe De Deurwaerdère, Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  16. 16
    Yunqi Xu, Junqiang Yan, Peng Zhou, Jiejie Li, Huimin Gao, Ying Xia, Qing Wang, Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease, Progress in Neurobiology, 2012, 97, 1, 1

    CrossRef

  17. 17
    Y. Zhang, A.-C. Granholm, K. Huh, L. Shan, O. Diaz-Ruiz, N. Malik, L. Olson, B. J. Hoffer, C. R. Lupica, A. F. Hoffman, C. M. Backman, PTEN deletion enhances survival, neurite outgrowth and function of dopamine neuron grafts to MitoPark mice, Brain, 2012, 135, 9, 2736

    CrossRef

  18. 18
    Szabolcs Farkas, Katalin Nagy, Zhisheng Jia, Tibor Hortobágyi, Andrea Varrone, Christer Halldin, László Csiba, Balázs Gulyás, Signal transduction pathway activity compensates dopamine D2/D3 receptor density changes in Parkinson's disease: a preliminary comparative human brain receptor autoradiography study with [3H]raclopride and [35S]GTPγS, Brain Research, 2012, 1453, 56

    CrossRef

  19. 19
    Szabolcs Farkas, Katalin Nagy, Zhisheng Jia, Tibor Harkany, Miklós Palkovits, Sean R. Donohou, Victor W. Pike, Christer Halldin, Domokos Máthé, László Csiba, Balázs Gulyás, The decrease of dopamine D2/D3 receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB1 cannabinoid receptors in Parkinson's disease: A preliminary autoradiographic study with the selective dopamine D2/D3 antagonist [3H]raclopride and the novel CB1 inverse agonist [125I]SD7015, Brain Research Bulletin, 2012, 87, 6, 504

    CrossRef

  20. 20
    A Jon Stoessl, WR Wayne Martin, Martin J McKeown, Vesna Sossi, Advances in imaging in Parkinson's disease, The Lancet Neurology, 2011, 10, 11, 987

    CrossRef

  21. 21
    Wei Sun, Kenji Sugiyama, Tetsuya Asakawa, Hiroshi Yamaguchi, Soichi Akamine, Yasuomi Ouchi, Yasuhiro Magata, Hiroki Namba, Dynamic changes of striatal dopamine D2 receptor binding at later stages after unilateral lesions of the medial forebrain bundle in Parkinsonian rat models, Neuroscience Letters, 2011, 496, 3, 157

    CrossRef

  22. 22
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  23. 23
    Wei Sun, Kenji Sugiyama, Xin Fang, Hiroshi Yamaguchi, Soichi Akamine, Yasuhiro Magata, Hiroki Namba, Different striatal D2-like receptor function in an early stage after unilateral striatal lesion and medial forebrain bundle lesion in rats, Brain Research, 2010, 1317, 227

    CrossRef

  24. 24
    Satoshi Kono, Yasuomi Ouchi, Tatsuhiro Terada, Hiroyuki Ida, Makiko Suzuki, Hiroaki Miyajima, Functional brain imaging in glucocerebrosidase mutation carriers with and without Parkinsonism, Movement Disorders, 2010, 25, 12
  25. 25
    Yu. S. Ukraintseva, N. V. Shchegolevskii, V. A. Korshunov, V. G. Kucheryanu, M. V. Ugryumov, A. S. Bazya, Modeling of the presymptomatic stage of parkinsonism in mice: Analysis of dopamine release in the striatum, Neurochemical Journal, 2010, 4, 2, 142

    CrossRef

  26. 26
    J. Schwarz, Nuklearmedizinisches Imaging bei Parkinson-Syndromen, Der Nervenarzt, 2010, 81, 10, 1160

    CrossRef

  27. 27
    Chrissa Sioka, Andreas Fotopoulos, Athanassios P. Kyritsis, Recent advances in PET imaging for evaluation of Parkinson’s disease, European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 8, 1594

    CrossRef

  28. 28
    Kenji Ishibashi, Yuko Saito, Shigeo Murayama, Kazutomi Kanemaru, Keiichi Oda, Kiichi Ishiwata, Hidehiro Mizusawa, Kenji Ishii, Validation of cardiac 123I-MIBG scintigraphy in patients with Parkinson’s disease who were diagnosed with dopamine PET, European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1, 3

    CrossRef

  29. 29
    Renju Kuriakose, A. Jon Stoessl, Recent Advances in Parkinson’S Disease - Translational and Clinical Research, 2010,

    CrossRef

  30. 30
    Susanne Nikolaus, Christina Antke, Hans-Wilhelm Müller, In vivo imaging of synaptic function in the central nervous system, Behavioural Brain Research, 2009, 204, 1, 1

    CrossRef

  31. 31
    Walter Maetzler, Inga Liepelt, Daniela Berg, Progression of Parkinson's disease in the clinical phase: potential markers, The Lancet Neurology, 2009, 8, 12, 1158

    CrossRef

  32. 32
    Gurutz Linazasoro, Dopamine Dysregulation Syndrome and Levodopa-Induced Dyskinesias in Parkinson Disease, Clinical Neuropharmacology, 2008, PAP,

    CrossRef

  33. 33
    Svetlana I Chefer, Alane S Kimes, John A Matochik, Andrew G Horti, Varughese Kurian, Dean Shumway, Edward F Domino, Edythe D London, Alexey G Mukhin, Estimation of D2-like Receptor Occupancy by Dopamine in the Putamen of Hemiparkinsonian Monkeys, Neuropsychopharmacology, 2008, 33, 2, 270

    CrossRef

  34. 34
    Marios Politis, Paola Piccini, Nicola Pavese, Seong-Beom Koh, David J. Brooks, Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo 11C-raclopride PET study, Experimental Neurology, 2008, 214, 1, 112

    CrossRef

  35. 35
    Erik S. Musiek, Drew A. Torigian, Andrew B. Newberg, Investigation of Nonneoplastic Neurologic Disorders with PET and MRI, PET Clinics, 2008, 3, 3, 317

    CrossRef

  36. 36
    Shyamal H. Mehta, John C. Morgan, Kapil D. Sethi, Neuroimaging and transcranial ultrasonography in Parkinson’s disease, Current Neurology and Neuroscience Reports, 2008, 8, 4, 297

    CrossRef

  37. 37
    Jo Ann V. Antenor-Dorsey, Richard Laforest, Stephen M. Moerlein, Tom O. Videen, Joel S. Perlmutter, Radiation dosimetry of N-([11C]methyl)benperidol as determined by whole-body PET imaging of primates, European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 4, 771

    CrossRef

  38. 38
    Nicolaas I. Bohnen, Satyanarayana Gedela, Priyantha Herath, Gregory M. Constantine, Robert Y. Moore, Selective hyposmia in Parkinson disease: Association with hippocampal dopamine activity, Neuroscience Letters, 2008, 447, 1, 12

    CrossRef

  39. 39
    R. Cham, S. A. Studenski, S. Perera, N. I. Bohnen, Striatal dopaminergic denervation and gait in healthy adults, Experimental Brain Research, 2008, 185, 3, 391

    CrossRef

  40. 40
    C. C. P. Verstappen, B. R. Bloem, C. A. Haaxma, W. J. G. Oyen, M. W. I. M. Horstink, Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson’s disease: an [123I]IBZM and [123I]FP-CIT SPECT study, European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 4, 502

    CrossRef

  41. 41
    Walter Koch, Christine Hamann, Perry E. Radau, Klaus Tatsch, Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?, European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 8, 1265

    CrossRef

  42. 42
    Susanne Nikolaus, Christina Antke, Konstantin Kley, Thorsten D. Poeppel, Hubertus Hautzel, Daniela Schmidt, Hans-Wilhelm Müller, Investigating the Dopaminergic Synapse In Vivo. I. Molecular Imaging Studies in Humans, Reviews in the Neurosciences, 2007, 18, 6

    CrossRef

  43. 43
    N. Matsukawa, M. Maki, T. Yasuhara, K. Hara, G. Yu, L. Xu, K.M. Kim, J.C. Morgan, K.D. Sethi, C.V. Borlongan, Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats, Brain Research, 2007, 1160, 113

    CrossRef

  44. 44
    Peter Riederer, Manfred Gerlach, Thomas Müller, Heinz Reichmann, Relating mode of action to clinical practice: Dopaminergic agents in Parkinson's disease, Parkinsonism & Related Disorders, 2007, 13, 8, 466

    CrossRef

  45. 45
    Thomas Eckert, Christine Edwards, The application of network mapping in differential diagnosis of parkinsonian disorders, Clinical Neuroscience Research, 2007, 6, 6, 359

    CrossRef

  46. 46
    Jayaraman Rao, Parkinson's Disease and Related Disorders, Part I, 2007,

    CrossRef

  47. 47
    Felix Geser, Christoph Globas, Ludger Schöls, Gregor Wenning, Spinocerebellar Degenerations: The Ataxias and Spastic Paraplegias, 2007,

    CrossRef

  48. 48
    Vijay Dhawan, David Eidelberg, Neurobiology of Disease, 2007,

    CrossRef

  49. 49
    Nancy R. Barbas, Cognitive, Affective, and Psychiatric Features of Parkinson's Disease, Clinics in Geriatric Medicine, 2006, 22, 4, 773

    CrossRef

  50. 50
    Nicolaas I. Bohnen, Rakié Cham, Postural Control, Gait, and Dopamine Functions in Parkinsonian Movement Disorders, Clinics in Geriatric Medicine, 2006, 22, 4, 797

    CrossRef

  51. 51
    M.J. Hurley, P. Jenner, What has been learnt from study of dopamine receptors in Parkinson's disease?, Pharmacology & Therapeutics, 2006, 111, 3, 715

    CrossRef

  52. 52
    Maria-João Ribeiro, Marcel Ricard, Sandrine Bourgeois, Marie-Angele Lièvre, Michel Bottlaender, Philippe Gervais, Frédéric Dollé, André Syrota, Biodistribution and radiation dosimetry of [11C]raclopride in healthy volunteers, European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 8, 952

    CrossRef

  53. 53
    K. R. Kessler, N. Hamscho, B. Morales, C. Menzel, F. Barrero, F. Vives, S. Gispert, G. Auburger, Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson’s syndrome, Journal of Neural Transmission, 2005, 112, 10, 1345

    CrossRef

  54. 54
    Yang Mei, Sun Shenggang, Cao Xuebing, Effect of PD I administration on dopamine receptors mRNAs expression in the lesioned striatum of PD rat model, Journal of Huazhong University of Science and Technology [Medical Sciences], 2005, 25, 6, 645

    CrossRef

  55. 55
    Emily R. Stern, Jon C. Horvitz, Lucien J. Côté, Jennifer A. Mangels, Maintenance of Response Readiness in Patients With Parkinson's Disease: Evidence From a Simple Reaction Time Task., Neuropsychology, 2005, 19, 1, 54

    CrossRef

  56. 56
    Q. Wang, P.H. Wang, C. McLachlan, P.T.-H. Wong, Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats, Brain Research, 2005, 1045, 1-2, 229

    CrossRef

  57. 57
    Andrew B. Newberg, Abass Alavi, The role of PET imaging in the management of patients with central nervous system disorders, Radiologic Clinics of North America, 2005, 43, 1, 49

    CrossRef

  58. 58
    Philippe Damier, Aspects neurochimiques de la maladie de Parkinson, EMC - Neurologie, 2004, 1, 1, 1

    CrossRef

  59. 59
    Klaus Seppi, Michael F.H. Schocke, Eveline Donnemiller, Regina Esterhammer, Christian Kremser, Christoph Scherfler, Anja Diem, Werner Jaschke, Gregor K. Wenning, Werner Poewe, Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease, Movement Disorders, 2004, 19, 12
  60. 60
    Andrew H. Evans, Durval C. Costa, Sveto Gacinovic, Regina Katzenschlager, John D. O'Sullivan, Simon Heales, Phillip Lee, Andrew J. Lees, L-dopa–responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings, Movement Disorders, 2004, 19, 10
  61. 61
    C. Briani, A. Cagnin, F. Chierichetti, M. Tiberio, L. Battistin, G. Pizzolato, Thiethylperazine-induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade, European Journal of Neurology, 2004, 11, 10
  62. 62
    Kazunori Kawamura, Yuichi Kimura, Hideo Tsukada, Tadayuki Kobayashi, Shingo Nishiyama, Takeharu Kakiuchi, Hiroyuki Ohba, Norihiro Harada, Kiyoshi Matsuno, Kenji Ishii, Kiichi Ishiwata, An increase of sigma1 receptors in the aged monkey brain, Neurobiology of Aging, 2003, 24, 5, 745

    CrossRef

  63. 63
    Takeshi Nakajima, Taro Nimura, Keiichiro Yamaguchi, Tadashi Ando, Masatoshi Itoh, Takashi Yoshimoto, Reizo Shirane, The impact of stereotactic pallidal surgery on the dopamine D2receptor in Parkinson disease: a positron emission tomography study, Journal of Neurosurgery, 2003, 98, 1, 57

    CrossRef

  64. 64
    Nicolaas I. Bohnen, Kirk A. Frey, The role of positron emission tomography imaging in movement disorders, Neuroimaging Clinics of North America, 2003, 13, 4, 791

    CrossRef

  65. 65
    Serge Przedborski, Vladimir Kosti_, Nir Giladi, David Eidelberg, Dopamine Receptors and Transporters, 2003,

    CrossRef

  66. 66
    Chisako Oyanagi, Yukinori Katsumi, Takashi Hanakawa, Takuya Hayashi, Din ha Duy Thuy, Kazuo Hashikawa, Yasuhiro Nagahama, Hidenao Fukuyama, Hiroshi Shibasaki, Comparison of Striatal Dopamine D2 Receptors in Parkinson's Disease and Progressive Supranuclear Palsy Patients Using [123I] Iodobenzofuran Single-Photon Emission Computed Tomography, Journal of Neuroimaging, 2002, 12, 4
  67. 67
    Kuo-Hsing Ma, Wen-Sheng Huang, Chien-Hsing Chen, Shin-Zong Lin, Shiaw-Pyng Wey, Gann Ting, Shwun-De Wang, Hwan-Wun Liu, Jiang-Chuan Liu, Dual SPECT of dopamine system using [99mTc]TRODAT-1 and [123I]IBZM in normal and 6-OHDA-lesioned formosan rock monkeys, Nuclear Medicine and Biology, 2002, 29, 5, 561

    CrossRef

  68. 68
    R. Sánchez-Pernaute, A.-L. Brownell, O. Isacson, Functional Imaging of the Dopamine System: In Vivo Evaluation of Dopamine Deficiency and Restoration, NeuroToxicology, 2002, 23, 4-5, 469

    CrossRef

  69. 69
    J.N Joyce, H.L Ryoo, T.B Beach, J.N Caviness, Mark Stacy, E.V Gurevich, Mark Reiser, C.H Adler, Loss of response to levodopa in Parkinson’s disease and co-occurrence with dementia: role of D3 and not D2 receptors, Brain Research, 2002, 955, 1-2, 138

    CrossRef

  70. 70
    Raúl de la Fuente-Fernández, A. Jon Stoessl, Parkinsonʼs disease: imaging update, Current Opinion in Neurology, 2002, 15, 4, 477

    CrossRef

  71. 71
    Thomas Müller, Sabiene Benz, Horst Przuntek, Tapping and Peg Insertion after Levodopa Intake in Treated and de novo Parkinsonian Patients, The Canadian Journal of Neurological Sciences, 2002, 29, 01, 73

    CrossRef

  72. 72
    Jeffrey N. Joyce, Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs, Pharmacology & Therapeutics, 2001, 90, 2-3, 231

    CrossRef

  73. 73
    Georg Berding, Per Odin, David J. Brooks, Guido Nikkhah, Cordula Matthies, Thomas Peschel, Mona Shing, Hans Kolbe, Jörg van den Hoff, Harald Fricke, Reinhard Dengler, Madjid Samii, Wolfram H. Knapp, Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [18F]FDG-PET, Movement Disorders, 2001, 16, 6
  74. 74
    J.N. Joyce, H. Ryoo, E.V. Gurevich, C. Adler, T. Beach, Ventral striatal D3 receptors and Parkinson's Disease, Parkinsonism & Related Disorders, 2001, 7, 3, 225

    CrossRef

  75. 75
    Jeffrey N. Joyce, Functional Neurobiology of Aging, 2001,

    CrossRef

  76. 76
    Kenichi Kashihara, Yasuhiro Manabe, Yoshihiko Shiro, Hitoshi Warita, Koji Abe, Effects of repeated methyl levodopa administration on apomorphine sensitivity of rotational behavior and striatal Fos expression of rats with unilateral 6-OHDA lesions, Neuroscience Research, 2000, 38, 3, 273

    CrossRef

  77. 77
    Brenda J. Anderson, S.John Gatley, David N. Rapp, Pamela S. Coburn-Litvak, Nora D. Volkow, The ratio of striatal D1 to muscarinic receptors changes in aging rats housed in an enriched environment, Brain Research, 2000, 872, 1-2, 262

    CrossRef

  78. 78
    D. Eidelberg, C. Edwards, M. Mentis, V. Dhawan, J.R. Moeller, Brain Mapping: The Disorders, 2000,

    CrossRef

  79. 79
    M.A Piggott, E.F Marshall, N Thomas, S Lloyd, J.A Court, E Jaros, D Costa, R.H Perry, E.K Perry, Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine, Neuroscience, 1999, 90, 2, 433

    CrossRef

  80. 80
    Carlo Colosimo, Manuela De Michele, Motor fluctuations in Parkinson's disease: pathophysiology and treatment, European Journal of Neurology, 1999, 6, 1
  81. 81
    Christine Dentresangle, Laurent Veyre, Didier Le Bars, Christian Pierre, Frank Lavenne, Pierre Pollak, Jeanine Guerin, Jean-Claude Froment, Emmanuel Brousolle, Striatal D2 dopamine receptor status in Parkinson's disease: An [18F]dopa and [11C]Raclopride PET study, Movement Disorders, 1999, 14, 6
  82. 82
    Angelo Antonini, Klaus L. Leenders, David Eidelberg, [11C]Raclopride-PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length, Annals of Neurology, 1998, 43, 2
  83. 83
    Gregor K. Wenning, Eveline Donnemiller, Roberta Granata, Georg Riccabona, Werner Poewe, 123I-β-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease, Movement Disorders, 1998, 13, 3
  84. 84
    Gabriella Künig, Klaus L. Leenders, Angelo Antonini, Peter Vontobel, Adolf Weindl, Hans M. Meinck, D2 receptor binding in dopa-responsive dystonia, Annals of Neurology, 1998, 44, 5
  85. 85
    Angelo Antonini, Ken Kazumata, Andrew Feigin, Francine Mandel, Vijay Dhawan, Claude Margouleff, David Eidelberg, Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET, Movement Disorders, 1998, 13, 2
  86. 86
    Han L. Ryoo, Dylan Pierrotti, Jeffrey N. Joyce, Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease, Movement Disorders, 1998, 13, 5
  87. 87
    A. Jon Stoessl, Thomas J. Ruth, Neuroreceptor imaging: new developments in PET and SPECT imaging of neuroreceptor binding (including dopamine transporters, vesicle transporters and post synaptic receptor sites), Current Opinion in Neurology, 1998, 11, 4, 327

    CrossRef

  88. 88
    N. D. Volkow, G. J. Wang, J. S. Fowler, Y. S. Ding, R. C. Gur, J. Gatley, J. Logan, P. J. Moberg, R. Hitzemann, G. Smith, N. Pappas, Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging, Annals of Neurology, 1998, 44, 1
  89. 89
    Anthony E. Lang, Andres M. Lozano, Parkinson's Disease, New England Journal of Medicine, 1998, 339, 15, 1044

    CrossRef

  90. 90
    A. Jon Stoessl, Functional Imaging Studies in Parkinson's Disease: The Non-Dopaminergic Systems,